Author

V. V. Van Deerlin

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Data-driven identification of repurposable drugs for ALS

Amyotrophic lateral sclerosis (ALS) is a severe disease that causes thousands of deaths annually. Current treatments are either limited in effectiveness or not broadly applicable. To discover new options, we conducted a genetics-based screen to identify drugs that could be repurposed for ALS. We analyzed genome-wid...

S. Saez-Atienzar, Luis A. Rojas-Colón, Ruth Chia et al. · npj Digital Medicine · 0 citations

Aug 2026

Association Between Postmortem Pathologic Burden and the Rate of Clinical Progression in Patients With Frontotemporal Lobar Degeneration.

Greater TDP-43 burden was most closely associated with antemortem clinical decline rather than cumulative aggregation through the disease course, suggesting that the temporal dynamics of protein aggregation may differ among FTLD proteinopathies, with implications for the interpretation of FTLD-Tau and FTLD-TDP‑specific...

R. Magee, Sharon X. Xie, DT Ohm et al. · Neurology · 1 citation

Open access Aug 2026

Activated microglial phenotypes in the hippocampal CA2 subfield are implicated in Lewy body disease progression

The data show that activated microglial phenotypes in the CA2 of LBD patients are associated with worse clinical outcomes and retrograde n-asyn transmission, and suggest that measures of microglial states can refine LBD histopathological progression models.

Esteban Luna, K. Cousins, Sheina Emrani et al. · Acta Neuropathologica · 0 citations